Crescent Biopharma, Inc. (CBIO) stock
CBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 10/30
$14.15−0.22 (-1.53%)
Close on Nov 13, 2026Market cap $525.59MP/E –Yield –
Crescent Biopharma total assets
Total assets on the balance sheet at the end of each period.
Crescent Biopharma's total assets was $299.50M at Sep 30, 2026. For fiscal 2025 it was $240.29M, up 574.7% from the year before. Over ten years it grew 17.4% a year on average. The highest annual figure on record is $240.29M in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $240.29M | +574.7% |
| FY2024 | Dec 31, 2024 | $35.62M | -21.4% |
| FY2023 | Dec 31, 2023 | $45.32M | -12.5% |
| FY2022 | Dec 31, 2022 | $51.81M | -45.1% |
| FY2021 | Dec 31, 2021 | $94.35M | -33.9% |
| FY2020 | Dec 31, 2020 | $142.83M | -15.0% |
| FY2019 | Dec 31, 2019 | $167.97M | -21.8% |
| FY2018 | Dec 31, 2018 | $214.84M | +67.1% |
| FY2017 | Dec 31, 2017 | $128.58M | +203.3% |
| FY2016 | Dec 31, 2016 | $42.39M | -12.5% |
| FY2015 | Dec 31, 2015 | $48.46M | -15.4% |
| FY2014 | Dec 31, 2014 | $57.26M | +983.8% |
| FY2013 | Dec 31, 2013 | $5.28M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $299.50M | +116.6% |
| Q2 FY2026 | Jun 30, 2026 | $182.76M | +16.1% |
| Q1 FY2026 | Mar 31, 2026 | $199.13M | +3223.2% |
| Q4 FY2025 | Dec 31, 2025 | $240.29M | +574.7% |
| Q3 FY2025 | Sep 30, 2025 | $138.27M | +780.8% |
| Q2 FY2025 | Jun 30, 2025 | $157.43M | +544.7% |
| Q1 FY2025 | Mar 31, 2025 | $5.99M | -82.5% |
| Q4 FY2024 | Dec 31, 2024 | $35.62M | -21.4% |
| Q3 FY2024 | Sep 30, 2024 | $15.70M | -70.5% |
| Q2 FY2024 | Jun 30, 2024 | $24.42M | -60.5% |
| Q1 FY2024 | Mar 31, 2024 | $34.20M | -50.4% |
| Q4 FY2023 | Dec 31, 2023 | $45.32M | -12.5% |
| Q3 FY2023 | Sep 30, 2023 | $53.20M | -4.9% |
| Q2 FY2023 | Jun 30, 2023 | $61.82M | -5.0% |
| Q1 FY2023 | Mar 31, 2023 | $68.92M | -15.4% |
| Q4 FY2022 | Dec 31, 2022 | $51.81M | -45.1% |
| Q3 FY2022 | Sep 30, 2022 | $55.96M | -48.2% |
| Q2 FY2022 | Jun 30, 2022 | $65.04M | -47.7% |
| Q1 FY2022 | Mar 31, 2022 | $81.46M | -41.0% |
| Q4 FY2021 | Dec 31, 2021 | $94.35M | -33.9% |
| Q3 FY2021 | Sep 30, 2021 | $107.94M | -28.2% |
| Q2 FY2021 | Jun 30, 2021 | $124.38M | -21.5% |
| Q1 FY2021 | Mar 31, 2021 | $138.02M | -14.9% |
| Q4 FY2020 | Dec 31, 2020 | $142.83M | -15.0% |
| Q3 FY2020 | Sep 30, 2020 | $150.42M | -16.6% |
| Q2 FY2020 | Jun 30, 2020 | $158.35M | -17.7% |
| Q1 FY2020 | Mar 31, 2020 | $162.10M | -20.7% |
| Q4 FY2019 | Dec 31, 2019 | $167.97M | -21.8% |
| Q3 FY2019 | Sep 30, 2019 | $180.45M | -19.9% |
| Q2 FY2019 | Jun 30, 2019 | $192.33M | -18.4% |
| Q1 FY2019 | Mar 31, 2019 | $204.44M | -17.4% |
| Q4 FY2018 | Dec 31, 2018 | $214.84M | +67.1% |
| Q3 FY2018 | Sep 30, 2018 | $225.17M | +94.4% |
| Q2 FY2018 | Jun 30, 2018 | $235.70M | +93.8% |
| Q1 FY2018 | Mar 31, 2018 | $247.42M | +565.6% |
| Q4 FY2017 | Dec 31, 2017 | $128.58M | +203.3% |
| Q3 FY2017 | Sep 30, 2017 | $115.82M | – |
| Q2 FY2017 | Jun 30, 2017 | $121.62M | – |
| Q1 FY2017 | Mar 31, 2017 | $37.17M | – |
| Q4 FY2016 | Dec 31, 2016 | $42.39M | – |
See a number that looks wrong?